Evidence map›Paper›PMID 35163173›Full record

SynthesisInternational journal of molecular sciences2022

Janus Kinase Inhibitors Improve Disease Activity and Patient-Reported Outcomes in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 24,135 Patients.

Lilla Tóth, Márk F Juhász, László Szabó, Alan Abada, Fruzsina Kiss, Péter Hegyi, Nelli Farkas, György Nagy, Zsuzsanna Helyes

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Lilla TóthDepartment of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, H-7624 Pécs, Hungary.ORCID 0000-0001-5878-5232
Márk F JuhászInstitute for Translational Medicine, Szentágothai Research Centre, Medical School, University of Pécs, H-7624 Pécs, Hungary.
László SzabóInstitute for Translational Medicine, Szentágothai Research Centre, Medical School, University of Pécs, H-7624 Pécs, Hungary.
Alan AbadaInstitute for Translational Medicine, Szentágothai Research Centre, Medical School, University of Pécs, H-7624 Pécs, Hungary.ORCID 0000-0002-6047-4764
Fruzsina KissDepartment of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, H-7624 Pécs, Hungary.
Péter HegyiInstitute for Translational Medicine, Szentágothai Research Centre, Medical School, University of Pécs, H-7624 Pécs, Hungary.
Nelli FarkasInstitute for Translational Medicine, Szentágothai Research Centre, Medical School, University of Pécs, H-7624 Pécs, Hungary.
György NagyDepartment of Rheumatology and Clinical Immunology, Department of Internal Medicine and Oncology, Semmelweis University, H-1027 Budapest, Hungary.
Zsuzsanna HelyesDepartment of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, H-7624 Pécs, Hungary.
University of Pecs · HUSemmelweis University · HUSomogy Megyei Kaposi Mór Oktató Kórház · HUUniversity of Szeged · HU

Funding

Hungarian Academy of Sciences GINOP-2.3.2-15- 2016-00048 - STAY ALIVE and GINOP-2.3.4-15-2020-00010
6 · The paper itself

Abstract

Pain, fatigue, and physical activity are major determinants of life quality in rheumatoid arthritis (RA). Janus kinase (JAK) inhibitors have emerged as effective medications in RA and have been reported to exert direct analgesic effect in addition to reducing joint inflammation. This analysis aims to give an extensive summary of JAK inhibitors especially focusing on pain and patient reported outcomes (PRO). MEDLINE, CENTRAL, Embase, Scopus, and Web of Science databases were searched on the 26 October 2020, and 50 randomized controlled trials including 24,135 adult patients with active RA met the inclusion criteria. JAK inhibitors yielded significantly better results in all 36 outcomes compared to placebo. JAK monotherapy proved to be more effective than methotrexate in 9 out of 11 efficacy outcomes. In comparison to biological disease-modifying antirheumatic drugs, JAK inhibitors show statistical superiority in 13 of the 19 efficacy outcomes. Analgesic effect determined using the visual analogue scale and American College of Rheumatology (ACR) 20/50/70 response rates was significantly greater in the JAK group in all comparisons, and no significant difference regarding safety could be explored. This meta-analysis gives a comprehensive overview of JAK inhibitors and provides evidence for their superiority in improving PROs and disease activity indices in RA.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidDatabases, FactualHumansJanus Kinase InhibitorsJanus KinasesMethotrexatePainPain ManagementPatient Reported Outcome MeasuresRandomized Controlled Trials as TopicTreatment OutcomeAntirheumatic AgentsJanus Kinase InhibitorsJanus KinasesMethotrexateanalgesic effectJAK inhibitorsmeta-analysisPROsrheumatoid arthritis

Identifiers

PMID35163173
PMCPMC8836107
OpenAlexW4207035552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.